Note for colleagues: this is a plain-language educational summary of a recently presented trial, prepared for a general audience. Please verify all figures against the primary publication before relying on them clinically.
For years, the strongest outcome data for PCSK9 inhibitors sat almost entirely in the secondary-prevention space - patients who had already had a heart attack or stroke. VESALIUS-CV extends that evidence to high-risk patients who have not yet had a first event, a group that dominates cardiology clinics across central Gujarat.
Design. VESALIUS-CV randomised roughly 12,000 high-cardiovascular-risk patients without prior MI or stroke to evolocumab or placebo on top of background lipid-lowering therapy.
Entry required either documented atherosclerosis or high-risk diabetes, with a baseline LDL-C of at least 90 mg/dL. Median follow-up was about 4.6 years.
Efficacy. Evolocumab lowered LDL-C by roughly 55% at 48 weeks, taking the median from about 115 to about 45 mg/dL. This translated into a 31% relative risk reduction in the primary major-adverse-cardiovascular-event composite.
Investigators also reported nominal reductions in cardiovascular death (about 32%) and all-cause mortality (about 24%) - directionally reassuring, though these should be read as secondary or nominal signals rather than definitive mortality claims.
Diabetes subgroup (presented NLA 2026). In roughly 3,655 patients with diabetes but without known significant atherosclerosis, evolocumab reduced 3-point and 4-point MACE by about 29% and 21% respectively.
This is arguably the most practice-relevant slice, because it is genuine primary prevention in a metabolically high-risk group.
Why it matters for central Gujarat. Our patients often present with premature, aggressive atherosclerosis and a very high burden of diabetes, sometimes a decade before a first event.
VESALIUS-CV supports the direction of the 2026 ACC/AHA dyslipidemia guideline ("lower, sooner") and strengthens the case for intensive LDL-C lowering in selected high-risk primary-prevention patients - while cost and access remain the real-world limiting factors here.
Please verify the exact endpoint definitions, hazard ratios, confidence intervals and subgroup numbers against the primary publication (NEJM, and the AHA 2025 and NLA 2026 presentations) before relying on them clinically or quoting them to colleagues.